The company decided to submit the the MHRA, not the FDA. Not that they had a choice. The MHRA won't give a crap about the minimal compassionate use cases given they have 331 in the actual trial. They will give a crap about no patient level data in the convoluted control arm which is probably why this is sitting without movement. An RFI to which the company hasn't responded.
Market Data 
Markets 
